Evaluation of lymphoid-specific enhancer addition or substitution in a basic retrovirus vector.
Evaluation of lymphoid-specific enhancer addition or substitution in a basic retrovirus vector.
复制标题
评估基本逆转录病毒载体中淋巴特异性增强子的添加或替换。
DOI：
10.1089/hum.1991.2.4-307
复制
发表时间：
1991
影响因子：
4.2
通讯作者：
Belmont,JW
中科院分区：
文献类型：
--
作者：
Moore,KA;Scarpa,M;Kooyer,S;Utter,A;Caskey,CT;Belmont,JW
测试了两种带有淋巴特异性增强子的新型逆转录病毒载体，以改善组织培养细胞和小鼠骨髓移植受者中人腺苷脱氨酶（hADA）的表达。这些载体携带添加的人 T 细胞受体 α 链增强子 (ΔN2TADA) 或用鼠免疫球蛋白 μ 重链第一内含子增强子 (ΔN2μADA) 替代莫洛尼长末端重复 (LTR) 增强子。每个载体以大约106感染单位/ml的效价产生，并有效地将hADA转导到培养物中的鼠成纤维细胞和骨髓瘤细胞中。在增强子修饰载体和基本逆转录病毒载体（ΔN2ADA）之间没有观察到表达的数量差异。此外，每种载体都能在长期移植小鼠的淋巴、骨髓和红细胞中有效地表达 hADA。大多数转导骨髓受体在三种载体中均表现出人类酶的表达达 4-8 个月。
Two novel retroviral vectors bearing lymphoid-specific enhancers were tested for improved expression of human adenosine deaminase (hADA) in tissue culture cells and in mouse bone marrow transplant recipients. These vectors carried either an added human T-cell receptor α-chain enhancer (ΔN2TADA) or a substitution of the Moloney long terminal repeat (LTR) enhancer with the murine immunoglobulin μ heavy-chain first intron enhancer (ΔN2μADA). Each vector was produced at a titer of approximately 106infectious units/ml and efficiently transduced hADA into murine fibroblast and myeloma cells in culture. No quantitative difference in expression was observed between the enhancer modified vectors and the basic retrovirus vector (ΔN2ADA). In addition, each vector efficiently conferred hADA expression in lymphoid, myeloid, and erythroid cells of long-term transplanted mice. The majority of the transduced-marrow recipients demonstrated expression of the human enzyme for 4–8 months with each of the three vectors.